Headlands Technologies LLC Buys 12,989 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Headlands Technologies LLC increased its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 94.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,736 shares of the biopharmaceutical company’s stock after purchasing an additional 12,989 shares during the quarter. Headlands Technologies LLC’s holdings in Agios Pharmaceuticals were worth $879,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of AGIO. Venturi Wealth Management LLC acquired a new position in Agios Pharmaceuticals during the 4th quarter valued at about $33,000. Wingate Wealth Advisors Inc. acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $53,000. KBC Group NV boosted its stake in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 611 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth $146,000. Finally, AlphaQuest LLC raised its position in shares of Agios Pharmaceuticals by 106.2% during the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 2,338 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 price objective for the company. Scotiabank boosted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Royal Bank of Canada lifted their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and an average target price of $56.57.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $28.44 on Thursday. The firm’s 50 day moving average price is $32.88 and its two-hundred day moving average price is $40.49. Agios Pharmaceuticals, Inc. has a twelve month low of $26.66 and a twelve month high of $62.58. The firm has a market cap of $1.63 billion, a P/E ratio of 2.51 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.